Literature DB >> 7673014

Prognostic value of tumor regression during radiotherapy for head and neck cancer: a prospective study.

C Jaulerry1, B Dubray, F Brunin, J Rodriguez, D Point, B Blaszka, B Asselain, V Mosseri, J Brugere, J M Cosset.   

Abstract

OBJECTIVE: Prospective evaluation of tumor regression during external irradiation for head and neck squamous cell carcinomas and its association with long-term local control. METHODS AND MATERIALS: Two hundred twenty-eight patients with histologically confirmed squamous cell carcinoma [oral cavity: 59 (26%), oropharynx: 65 (29%), hypopharynx: 37 (16%), larynx: 67 (29%)] were included between January 1986 and December 1990. Curative intent external irradiation delivered 65-70 Gy over a period of 7 weeks (five 2 Gy fractions per week). Tumor regression was evaluated clinically and endoscopically every week.
RESULTS: Tumor regression, assessed at 2 weeks, was as follows: no response: 62 (30%), 25% response: 121 (59%); 50% response: 23 (11%). At 5 weeks, 9 (4%) patients showed 0-25% regression, 75 (33%) showed 50% regression, 115 (50%) showed 75% regression, and 29 (13%) showed complete regression. Median follow-up was 79 months (range: 6-96 months). The local control probability was 68% (62-74%) at 2 years, 65% (59-70%) at 5 years. Univariate analysis showed that, at 2 weeks, local control was significantly different between the nonresponders and the patients with 25% or greater response (p < 0.025) and that, at the fifth week, local control was very different between the major responders (75 and 100%) and the minor responders (0-50%) (p < 0.0001). Multivariate analysis (Cox Proportional Hazards Model) showed that the probability of local relapse was significantly and independently increased for minor regression at 5 weeks [Relative risk (RR) of failure was 2.3 (1.4-3.7)], for nonlaryngeal tumors [RR: 2.4 (1.3-4.5)], and for Stage T3-T4 [RR:2.4 (1.4-4)]. Three prognostic groups can, therefore, be proposed: 1) low risk of recurrence when regression > or = 75% and laryngeal tumor or T1-T2 tumors in other sites: 106 (46.5%) patients, 2-year local control probability: 84% (77-92%); 2) high risk of recurrence: regression < or = 50% and T3-T4 nonlaryngeal tumors: 44 (19%) patients, 2-year local control probability: 27% (13-41%); 3) intermediate risk of recurrence: 78 (34.5%) patients, 2-year local control probability: 69% (58-80%).
CONCLUSION: The present study suggests that tumor regression during external radiotherapy is an independent predictive factor of local control in head and neck carcinomas.

Entities:  

Mesh:

Year:  1995        PMID: 7673014     DOI: 10.1016/0360-3016(95)00157-T

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma.

Authors:  Vincent Vandecaveye; Piet Dirix; Frederik De Keyzer; Katya Op de Beeck; Vincent Vander Poorten; I Roebben; Sandra Nuyts; Robert Hermans
Journal:  Eur Radiol       Date:  2010-02-24       Impact factor: 5.315

2.  Prediction and monitoring of the response to chemoradiotherapy in oral squamous cell carcinomas using a pharmacokinetic analysis based on the dynamic contrast-enhanced MR imaging findings.

Authors:  Toru Chikui; Shintaro Kawano; Toshiyuki Kawazu; Masamitsu Hatakenaka; Syouzou Koga; Masahiro Ohga; Yoshio Matsuo; Syunya Sunami; Tsuyoshi Sugiura; Yoshiyuki Shioyama; Makoto Obara; Kazunori Yoshiura
Journal:  Eur Radiol       Date:  2011-03-12       Impact factor: 5.315

3.  Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck.

Authors:  Daniel A Hamstra; Kuei C Lee; Bradford A Moffat; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

4.  Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study.

Authors:  Yao Ding; John D Hazle; Abdallah S R Mohamed; Steven J Frank; Brian P Hobbs; Rivka R Colen; G Brandon Gunn; Jihong Wang; Jayashree Kalpathy-Cramer; Adam S Garden; Stephen Y Lai; David I Rosenthal; Clifton D Fuller
Journal:  NMR Biomed       Date:  2015-10-09       Impact factor: 4.044

5.  Comparison between radiation-induced cell cycle delay in lymphocytes and radiotherapy response in head and neck cancer.

Authors:  R Tell; T Heiden; F Granath; A L Borg; S Skog; R Lewensohn
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

6.  Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT.

Authors:  Munetaka Matoba; Hiroyuki Tuji; Yuzo Shimode; Tamaki Kondo; Kiyotaka Oota; Hisao Tonami
Journal:  J Radiat Res       Date:  2015-03-31       Impact factor: 2.724

7.  Radiation therapy for nasopharyngeal carcinoma: the predictive value of interim survival assessment.

Authors:  Ryo Toya; Ryuji Murakami; Tetsuo Saito; Daizo Murakami; Tomohiko Matsuyama; Yuji Baba; Ryuichi Nishimura; Toshinori Hirai; Akiko Semba; Eiji Yumoto; Yasuyuki Yamashita; Natsuo Oya
Journal:  J Radiat Res       Date:  2016-05-29       Impact factor: 2.724

8.  Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study.

Authors:  C Paterson; S Allwood-Spiers; I McCrea; J Foster; M McJury; M Thomson; M Sankaralingam; D Grose; A James; M Rizwanullah; P McLoone; A Chalmers; A Duffton
Journal:  Clin Transl Radiat Oncol       Date:  2017-01-10

9.  Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study.

Authors:  Ning Zhang; Shao-Bo Liang; Yan-Ming Deng; Rui-Liang Lu; Hai-Yang Chen; Hai Zhao; Zhi-Qian Lv; Shao-Qiang Liang; Lin Yang; Dong-Sheng Liu; Yong Chen
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.